A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/7024 (2006.01) A61K 31/70 (2006.01) A61P 7/02 (2006.01)
Patent
CA 2472957
The invention relates to a dose of 2.5 mg of the pentasaccharide methyl O- (2,3,4-tri-O-methyl-6-O-sulfo-.alpha.-D-glucopyranosyl)-(1.fwdarw.4)-O-(2,3-di- O-methyl-.beta.-D-glucopyranosyl uronic acid)-(1.fwdarw.4)-O-(2,3,6-tri-O- sulfo-.alpha.-D-glucopyranosyl)-(1.fwdarw.4)-O-(2,3-di-O-methyl-.alpha.-L- idopyranosyl uronic acid)-(1.fwdarw.4)-2,3,6-tri-O-sulfo-.alpha.-D- glucopyranoside or a pharmaceutically acceptable salt thereof for use in therapy, in particular for the treatment and/or secondary prophylaxis of venous thromboembolic events in patients with deep venous thrombosis.
La présente invention concerne une dose de 2,5 mg de pentasaccharide méthyle O-(2,3,4-tri-O-méthyl-6-O-sulfo-.alpha.-D-glucopyranosyl)-(1?4)-O-(acide 2,3-di-O-méthyl-.beta.-D-glucopyranosyle uronique)-(1?4)-O-(2,3,6-tri-O-sulfo-.alpha.-D-glucopyranosyl)-(1?4)-O-(acide 2,3-di-O-méthyl-.alpha.-L-idopyranosyle uronique)-(1?4)-2,3,6-tri-O-sulfo-.alpha.-D-glucopyranoside ou d'un sel de celui-ci, acceptable d'un point de vue pharmaceutique, utilisée dans le cadre d'une thérapie, notamment pour traiter et/ou prévenir de manière secondaire des événements thromboemboliques veineux chez des patients présentant une thrombose veineuse profonde.
Kirby Eades Gale Baker
Sanofi-Aventis
Sanofi-Synthelabo
LandOfFree
Idraparinux (sanorg 34006) for treatment and secondary... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Idraparinux (sanorg 34006) for treatment and secondary..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Idraparinux (sanorg 34006) for treatment and secondary... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1557999